In this episode, we address the growing clinical concern of lean-mass loss associated with GLP-1 receptor agonists such as semaglutide and tirzepatide, where studies show 20 to 45 percent of weight lost can come from muscle tissue. The discussion examines the mechanisms behind this risk and presents evidence-based strategies — including higher protein intake of 1.2 to 1.6 grams per kilogram of body weight and regular resistance training — to preserve muscle while achieving the metabolic benefits of these medications. Practical guidance is provided for patients and clinicians seeking to optimize body composition outcomes during treatment.